TMS for Schizophrenia and Self-Agency
This study is investigating how a device called the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM, which uses transcranial magnetic stimulation (TMS), might help people with schizophrenia. Researchers want to understand why some people with schizophrenia have difficulty with "self-agency" (knowing if an action or thought is their own) and if TMS can improve this. They will apply TMS to a specific brain area and measure changes in behavior and brain activity. You may be able to join if you are between 18 and 64 years old, in good general health, and speak English as your first language. Participants with schizophrenia must also have a stable diagnosis. The study is currently recruiting 160 participants, including both healthy volunteers and individuals with schizophrenia.
- Study design
- This is a randomized controlled trial involving 160 participants, including both healthy controls and individuals with schizophrenia. Participants will be randomly assigned to receive active TMS or TMS targeting a control site.
- What's involved
- You will undergo assessments for eligibility, including cognitive, clinical, and daily functioning assessments, structural MRI, and MEGI scans. After baseline, you will receive TMS and have follow-up assessments immediately after and up to one week later.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed immediately after TMS and up to one week later.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Karuna Subramaniam, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Self-Agency Behavioral Change during Reality Monitoring after TMS vs Baseline (metrics of accuracy)From baseline, to immediately after TMS, up to 1 week
Change in retrieval accuracy of self-generated information during reality monitoring task from baseline to post-TMS. No scales used.
- Self-Agency Behavioral Change during Speech Monitoring after TMS vs Baseline (metrics of speech perturbation units)From baseline, to immediately after TMS, up to 1 week
Change in speech corrective responses during altered vs. unaltered auditory feedback, measured in units of speech perturbation (cents) from baseline to post-TMS. No scales used.
- MEGI Neural Activity Change related to Self-Agency during Reality Monitoring after TMS vs Baseline (metrics of neural beta activation units)From baseline, to immediately after TMS, up to 1 week
Whole-brain neural activity change related to self-agency by contrasting oscillatory activity during encoding and retrieval of self-generated information with encoding and retrieval of externally-derived information (with focus on mPFC and parietal cortices as our region-of-interest (ROI)), measured in beta weights neural signal change from baseline to post-TMS. No scales used.
- MEGI Neural Activity Change related to Self-Agency during Speech Monitoring after TMS vs Baseline (metrics of neural beta activation units)From baseline, to immediately after TMS, up to 1 week
Whole-brain neural activity related to self-agency by contrasting oscillatory activity related to speech onset during altered auditory feedback with activity related to speech onset during unaltered auditory feedback (with focus on mPFC and parietal cortices for ROI analyses) measured in beta weights neural signal change from baseline to post-TMS. No scales used.